PainReform shares are trading lower after the company announced pricing of a $2.7 million concurrent registered direct offering and private placement.
Portfolio Pulse from Benzinga Newsdesk
PainReform announced the pricing of a $2.7 million concurrent registered direct offering and private placement, causing its shares to trade lower.

July 12, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PainReform's stock price is trading lower after the company announced a $2.7 million concurrent registered direct offering and private placement.
The announcement of a new stock offering typically leads to a decrease in the company's stock price in the short term. This is because existing shares are diluted, and investors may sell off their shares due to the increased supply. In this case, PainReform's announcement of a $2.7 million concurrent registered direct offering and private placement has led to a decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100